Replimune Group, Inc. Shares Purchased by Wellington Management Group LLP
REPL Stock | USD 6.32 0.61 10.68% |
About 55% of Replimune's institutional investors are presently thinking to get in. The analysis of overall sentiment of trading Replimune Group stock suggests that some investors are interested at this time. Replimune's investing sentiment shows overall attitude of investors towards Replimune Group.
Replimune | Build AI portfolio with Replimune Stock |
Wellington Management Group LLP boosted its position in Replimune Group, Inc. by 352.5 percent during the 4th quarter, according to the company in its most recent disclosure with the Securities Exchange Commission. The institutional investor owned 1,096,744 shares of the companys stock after acquiring an additional 854,346 shares during the quarter.
Read at thelincolnianonline.com
![]() |
Replimune Fundamental Analysis
We analyze Replimune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Replimune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Replimune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Replimune is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Replimune Group Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Replimune stock to make a market-neutral strategy. Peer analysis of Replimune could also be used in its relative valuation, which is a method of valuing Replimune by comparing valuation metrics with similar companies.
Peers
Replimune Related Equities
YMAB | Y MAbs | 103.34 | ||||
SNDX | Syndax Pharmaceuticals | 21.10 | ||||
LRMR | Larimar Therapeutics | 12.99 | ||||
CRNX | Crinetics Pharmaceuticals | 3.61 | ||||
MRUS | Merus BV | 2.09 | ||||
PCVX | Vaxcyte | 0.03 | ||||
SRRK | Scholar Rock | 0.03 | ||||
STOK | Stoke Therapeutics | 1.37 | ||||
STRO | Sutro Biopharma | 2.41 |
Check out Replimune Hype Analysis, Replimune Correlation and Replimune Performance. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.